Merck contract changes
Effective April 1st, 2025, Merck membership will be divided into multiple rosters:
- Roster 1: Includes members that receive discounted pricing in Product Group 2 only as well as a discount on Gardasil
- Roster 2: Includes members that receive discounted pricing in Product Groups 1 and 2
Merck product groups and their affiliated vaccines are listed below:
- Product Group 1: includes Pneumovax23, Vaxneuvance, Gardasil 9, VAQTA, and PedvaxHIB
- Product Group 2: includes RotaTeq, MMRII, Varivax, ProQuad, Recombivax (ped, adolescent, adult, and dialysis)
Starting July 21st, 2025, Merck has added an additional roster to account for their new RSV vaccine, Enflonsia
- Roster 3: Includes members that only purchase Enflonsia from Merck
RSV
If an office is interested in purchasing RSV vaccinations through the Child Health Advantage program, the office must hold a contract with the corresponding manufacturer. The available RSV vaccinations and age requirements are listed below.
To learn more about the vaccinations, please visit their respective websites or contact the office manufacturer rep. If an office wishes to get contracted with one of the following vaccinations, contact the Child Health Advantage program.
- Merck’s Enflonsia is available for children under 8 months of age born during or entering their first RSV season.
- GSK’s Arexvy vaccination is available for adults 50 and older.
- Pfizer’s Abrysvo vaccination is available for adults 60 and older. Abrysvo is also a maternal immunization available between 32 to 36 weeks during pregnancy.
- Sanofi’s Beyfortus vaccination is available during RSV season for newborns under one year old to children up to twenty-four months who are at high risk during RSV season.
